Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (American Journal of Clinical Dermatology, (2021), 22, 5, (693-707), 10.1007/s40257-021-00618-3)

Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin L. Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Min Zhang, Saleem A. Farooqui, William Romero, Andrew J. Thorpe, Ricardo Rojo, Susan Johnson

Research output: Contribution to journalComment/debatepeer-review

Abstract

SpringerLink on 18 August 2021. After publication in volume 22, issue 5, pages 693–707, the authors highlighted that, in Supplemental Table 1, the overall patient numbers for the JADE MONO-2 and JADE COMPARE studies were incorrect. These errors have been rectified and a new corrected version of Supplementary file 1 has been uploaded with the manuscript on SpringerLink. The original article has been corrected.

Original languageEnglish (US)
Pages (from-to)905
Number of pages1
JournalAmerican Journal of Clinical Dermatology
Volume22
Issue number6
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (American Journal of Clinical Dermatology, (2021), 22, 5, (693-707), 10.1007/s40257-021-00618-3)'. Together they form a unique fingerprint.

Cite this